BioPharmSignal logoBioPharmSignal

Biotech News

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

Eagle Pharmaceuticals (EGRX)Eagle PharmaceuticalsCompany update

WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders, which is scheduled to be held virtually on October 17, 2025 at 10:00 a.m.

Related news

EGRXEagle Pharmaceuticals2025-10-15 20:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2025-10-06 23:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

View all latest news

Eagle Pharmaceuticals

Eagle Pharmaceuticals is a specialty pharmaceutical company focused on hospital and acute-care products. Its business has historically centered on commercialization of focused injectable or hospital-based medicines.

Recent company news

EGRXEagle Pharmaceuticals2026-01-14 15:21 EST

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

EGRXEagle Pharmaceuticals2025-10-30 10:50 EST

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2025-10-21 20:05 EST

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

EGRXEagle Pharmaceuticals2025-10-15 20:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2025-10-06 23:30 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

Stock data

Close
0.05 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States